Danish dermatology company LEO Pharma will acquire Replay, a gene therapy company focused on developing treatments for rare genetic dermatological conditions.
The $50 million acquisition gives LEO access to Replay’s gene therapy platform, which leverages herpes simplex virus’ (HSV) unique capacity to deliver large genes, making it particularly well suited for addressing rare, genetically driven dermatological conditions. The genetically modified HSV therapy is formulated as a topical gel that targets the deficient gene when applied directly to the skin. Replay’s lead pipeline candidate is currently in preclinical studies for the treatment of dystrophic epidermolysis bullosa (DEB).
Replay launched in 2022 with a $55 million seed funding round. The San Diego-based company’s portfolio of genomic medicine technologies aims to solve the key challenges currently limiting clinical progress, including the need for increased payload capacity and off-the-shelf cell therapies that substantially reduce cost of goods, improve production speed, volume and consistency, and expand the potential for genome engineering.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!